Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Pathos AI announced multi-year collaborations with Bristol Myers Squibb (BMY) and Tempus AI (TEM) to advance drug development for neurological conditions.
Tempus will build a de-identified dataset tracking outcomes over time for hundreds of thousands of patients with neurological conditions. Pathos will license it under a five-year, $55 million agreement and apply its Foundry AI platform to study disease biology and inform clinical-trial design, beginning with Alzheimer’s disease and other neurological conditions.
Bristol Myers Squibb leads Pathos’s Series E financing and gains multi-year, non-exclusive access to Foundry across its broader research and development portfolio, plus three-year exclusive rights to support neuroscience development programs. Bristol Myers Squibb aims to use the platform and dataset to better understand disease progression and design more precise trials.
Tempus AI (TEM) signed a multi-year agreement for Bristol Myers Squibb (BMY) to license its oncology data through 2031. The agreement covers de-identified data combining multiple types of information to support biological and clinical insights, drug target discovery and therapeutic development across BMS’s oncology portfolio.
BMS will also gain access to Tempus’ Lens Platform, where researchers can train and run AI models using de-identified data and dedicated computing infrastructure. The agreement expands an existing relationship involving AI and real-world data for clinical trial design in oncology and neuroscience.
Tempus AI (NASDAQ: TEM) presented study results showing greater than 80% sensitivity across all 12 biomarkers assessed in advanced lung cancer.
The multi-center analysis covered 60,459 advanced non-small cell lung cancer cases across 56,969 patients. Sensitivity, a measure of how often a test identifies biomarker-positive cases, exceeded 90% for several biomarkers. The panel uses routine hematoxylin and eosin pathology images to predict biomarker status. Results were presented at the ESMO Congress 2026 in Madrid.
The panel remains in development. Tempus sees potential to help identify patients needing confirmatory biomarker testing. The study forms part of an ongoing collaboration with Pfizer addressing diagnostic barriers and supporting biomarker testing.
Tempus AI (TEM) will report its third-quarter 2026 financial results before U.S. markets open on November 2, 2026.
The quarter ended September 30, 2026. Founder and CEO Eric Lefkofsky and Chief Financial Officer Jim Rogers will lead a conference call and live audio webcast at 8:45 a.m. ET to discuss results and provide a business update. A recording will be available on the investor relations website after the call.
Tempus AI (TEM) subsidiary Ambry Genetics launched GenomeNext and GenomeReveal, a whole genome sequencing solution designed to help diagnose rare diseases.
GenomeNext uses a pangenome reference representing human genetic diversity, while GenomeReveal integrates RNA analysis to help interpret certain DNA findings. Testing includes Ambry’s Patient for Life program, which proactively reanalyzes patient data as knowledge of gene-disease relationships evolves. Ambry cited published research showing positive reclassifications in 5% of initially negative or uncertain exome sequencing cases; that finding is not a reported result for the newly launched tests.
Tempus (TEM) announced an expanded, multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene.
The therapy, also known as V940/mRNA-4157, is jointly developed by Moderna and Merck. It is being evaluated with Merck’s KEYTRUDA (pembrolizumab) in patients with completely resected stage IIB-IV melanoma and other cancer types. The collaboration builds on joint efforts initiated last year and supports preparations for potential commercialization.
Tempus will manage the collection and transfer of tumor tissue and blood samples required for next-generation sequencing (NGS), a method of reading genetic information. Subject to applicable regulatory approvals, Tempus will also provide NGS services to support the therapy’s design and manufacturing process. Financial terms were not disclosed.
Tempus AI (TEM) announced acceptance of 13 abstracts for presentation at the ESMO Congress, taking place October 23–27, 2026, in Madrid.
The research covers cancer biology, treatment response and patient outcomes across several solid tumors. Topics include prostate cancer, early-onset breast cancer, ovarian cancer associated with ATM mutations, and outcomes with trastuzumab deruxtecan in advanced gynecologic malignancies. Other presentations address AI-enabled lung cancer pre-screening using pathology images and interim results of the multicenter LOLA Project on blood-based genomic testing. Scheduled presentations run October 23, 25 and 26, alongside two e-posters.
Tempus AI (TEM) received FDA 510(k) clearance for ECG-MR, software that flags signs associated with undiagnosed moderate or severe mitral regurgitation.
The fourth FDA-cleared Tempus ECG-AI product analyzes resting 12-lead electrocardiograms, or ECGs, and gives a binary output to help identify patients for further evaluation, such as diagnostic imaging. Mitral regurgitation occurs when blood leaks backward through the mitral valve. The software is intended for clinical diagnostic ECGs recorded at a healthcare facility from patients aged 65 or older who are at risk of cardiovascular disease, have had no mitral valve intervention and have no prior diagnosis of moderate or severe mitral regurgitation.
It is not a stand-alone diagnostic tool or for serial monitoring, and it should not be used on ECGs with paced rhythms. Results should be read alongside the original ECG, other tests, symptoms and clinical history.
Tempus AI (TEM) and Recursion Pharmaceuticals (RXRX) have extended their multi-year data license agreement and signed a new RNA foundation model license. The collaboration, first established in 2023, is now extended through November 2029.
As part of the extension, the parties amended the Annual License Fees under their Master Agreement, replacing discretionary license fees potentially totaling $84 million over the next two years with committed payments totaling $42 million over the next three years. Separately, Recursion granted Tempus a non-exclusive, worldwide license to its proprietary RNA sequencing model, “TxFM”, under a new license agreement, supporting both companies’ efforts to apply foundation models to precision medicine.
Tempus AI (TEM) announced a multi‑year initiative to build a research platform containing 100,000 disease‑specific whole‑genome sequences linked to longitudinal clinical information, with a long‑term goal of scaling to 1 million genomes.
The company describes this as the first de‑identified multimodal whole‑genome sequencing dataset centered on disease populations and patient outcomes, optimized for AI research. The new whole‑genome sequencing data will be integrated into Tempus’ existing multimodal environment, combining genomics with clinical histories, imaging, pathology and outcomes. Through the Tempus Lens platform, researchers and model developers will be able to analyze the data and build or validate AI models within a model‑ready environment. Development is underway, an initial dataset is accessible via an Early Adopter Program, and broader availability is planned for mid‑2027.